Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis
Public ClinicalTrials.gov record NCT05556096. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel, Multicenter Study to Evaluate the Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis
Study identification
- NCT ID
- NCT05556096
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Enrollment
- 261 participants
Conditions and interventions
Conditions
Interventions
- ALXN1720 Combination Product
- Placebo Combination Product
Combination Product
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Not listed
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 20, 2022
- Primary completion
- May 26, 2025
- Completion
- Aug 30, 2027
- Last update posted
- Apr 20, 2026
2022 – 2027
United States locations
- U.S. sites
- 23
- U.S. states
- 16
- U.S. cities
- 23
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Orange | California | 92868 | — |
| Research Site | Fort Collins | Colorado | 80528 | — |
| Research Site | Washington D.C. | District of Columbia | 20007 | — |
| Research Site | Bradenton | Florida | 34209 | — |
| Research Site | Maitland | Florida | 32751 | — |
| Research Site | Tampa | Florida | 33612 | — |
| Research Site | Augusta | Georgia | 30912 | — |
| Research Site | Gainesville | Georgia | 30501 | — |
| Research Site | Savannah | Georgia | 31406 | — |
| Research Site | Springfield | Illinois | 62769 | — |
| Research Site | Kansas City | Kansas | 66160 | — |
| Research Site | Lexington | Kentucky | 40503 | — |
| Research Site | Detroit | Michigan | 48202 | — |
| Research Site | East Lansing | Michigan | 48824 | — |
| Research Site | Las Vegas | Nevada | 89117 | — |
| Research Site | Patchogue | New York | 11772 | — |
| Research Site | Rochester | New York | 14620 | — |
| Research Site | Syracuse | New York | 13202 | — |
| Research Site | Chapel Hill | North Carolina | 27599 | — |
| Research Site | North Charleston | South Carolina | 29406 | — |
| Research Site | Houston | Texas | 77030 | — |
| Research Site | Richmond | Virginia | 23298 | — |
| Research Site | Morgantown | West Virginia | 26506 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 109 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05556096, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 20, 2026 · Synced Apr 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05556096 live on ClinicalTrials.gov.